One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Sintx Technologies, Inc.
SINT · NCM · Healthcare · Medical Devices
Current price
$1.55
52-week range
$1.40 - $4.46
Market cap
$11.72M
Balance sheet
Healthy
-206.17x Concerning
Net cash $439.00K. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 225.3% last year.
- Risk Return on equity was -255.9% last year — the company lost money on shareholders' equity.
What this company does
Sintx Technologies, Inc.
Sintx Technologies makes special ceramic materials, mostly for medical uses like implants and surgical tools, but also for things like airplanes. They make their money by selling these advanced materials and devices to other companies. This is important because it shows how they are trying to turn their research into actual products people buy.
How the company got here
Sintx Technologies, Inc. was founded in 1996 as Amedica Corporation, initially focusing on developing ceramic hip systems and biocompatibility data for spinal fusion devices. A significant turning point came in 2008 when the company achieved the first FDA clearance for a medical implant material that wasn't metal or plastic, but medical-grade silicon nitride. This breakthrough paved the way for its use in spinal surgery. Over the years, the company expanded its product line, gained regulatory approvals in international markets, and eventually rebranded as SINTX Technologies, Inc. in 2018 after divesting its retail spine business. More recently, the company has undergone a recapitalization and leadership restructuring to accelerate the commercialization of its silicon nitride technologies.
What it actually does
Sintx Technologies is a company that specializes in advanced ceramics, with a primary focus on silicon nitride. Think of silicon nitride as a super-strong, biocompatible material that can be used to make things that go inside the body or need to withstand tough conditions. The company researches, develops, manufactures, and sells products made from this material for both medical and industrial uses. They aim to leverage the unique properties of silicon nitride, such as its strength, ability to resist bacteria, and how well it shows up on X-rays, to create better products than what's currently available.
Medical Devices
This is Sintx's main area of business, where they use their silicon nitride material to create products for the healthcare industry. They have developed spinal fusion implants, which are devices used to help bones in the spine fuse together, and have had over 50,000 of these successfully implanted worldwide. They also offer an FDA-cleared system for foot and ankle reconstructive surgery called the SiNAPTIC® Foot & Ankle Osteotomy Wedge System. Beyond finished products, Sintx also works as an Original Equipment Manufacturer (OEM), meaning they supply their specialized silicon nitride material to other larger medical device companies to use in their own products. This segment is a significant focus, with the company actively pursuing partnerships and aiming to expand the use of their materials in areas like dental implants and orthopedic coatings.
Industrial Applications
While medical devices are a primary focus, Sintx also explores how its advanced ceramics can be used in non-medical fields. This includes developing materials for aerospace suppliers, where the strength and heat resistance of silicon nitride are valuable. They are also investigating antipathogenic applications, leveraging silicon nitride's ability to neutralize viruses and bacteria. This could lead to products like specialized filters or coatings for various industrial uses where hygiene and pathogen resistance are critical. This segment is more nascent compared to their medical business, with a focus on niche applications where the unique properties of their ceramics offer a distinct advantage.
What management is betting on now
Sintx's management is focused on accelerating the commercialization of their silicon nitride technology across both medical and industrial markets. A key strategy involves forging strategic partnerships and licensing agreements with established companies to expand the reach of their innovative materials. They are also investing in enhancing their advanced manufacturing capabilities, particularly in 3D printing for patient-specific implants. The company aims to leverage its strong intellectual property portfolio and its unique material properties to drive growth, focusing on execution and building commercial momentum to translate their technological advancements into tangible business results.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-1.27M
FY2025 Q1
$-1.36M
FY2025 Q2
$-2.41M
FY2025 Q3
$-2.60M
FY2025 Q4
$-2.39M
FY2026 Q1
$-2.50M
FY2026 Q2
$-2.85M
FY2026 Q3
$-1.51M
Revenue
$2.19M
Net income
$-1.59M
Diluted EPS
-0.24
Operating cash flow
$-1.37M
Free cash flow
$-1.51M
Fetching…
Sources
Revenue
$452.00K
Net income
$-2.71M
Diluted EPS
-0.75
Operating cash flow
$-2.77M
Free cash flow
$-2.85M
Fetching…
Sources
Revenue
$380.00K
Net income
$-2.82M
Diluted EPS
-0.70
Operating cash flow
$-2.49M
Free cash flow
$-2.50M
Fetching…
Sources
Revenue
$290.00K
Net income
$-2.21M
Diluted EPS
-0.50
Operating cash flow
$-2.34M
Free cash flow
$-2.39M
Fetching…
Sources
Revenue
$208.00K
Net income
$-3.54M
Diluted EPS
-3.46
Operating cash flow
$-2.52M
Free cash flow
$-2.60M
Fetching…
Sources
Revenue
$151.00K
Net income
$-2.32M
Diluted EPS
-0.91
Operating cash flow
$-2.41M
Free cash flow
$-2.41M
Fetching…
Sources
Revenue
$369.00K
Net income
$-2.29M
Diluted EPS
-1.29
Operating cash flow
$-1.30M
Free cash flow
$-1.36M
Fetching…
Sources
Revenue
$542.00K
Net income
$-1.70M
Diluted EPS
-4.51
Operating cash flow
$-1.12M
Free cash flow
$-1.27M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.55
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $439,000 - more cash than debt. Interest coverage -206.2x.
Net debt
$-439.00K
Interest coverage
-206.17x
Sintx Technologies, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SINT
BASELINE
Sintx Technologies, Inc.
Total debt $3.15M Interest coverage -206.17x This is the baseline the peer rows are being compared against.
Total debt $26.01M Interest coverage 1.98x This peer still has a real interest-payment cushion, while SINT does not.
Total debt $593.95M Interest coverage -1.26x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SINT
1 Reward
1 Risk
Rewards
-
Revenue grew 225.3% last year.
Risks
-
Return on equity was -255.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.46x
P/B
2.10x
P/S
8.81x
EV/EBITDA
-0.91x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
52.9%
Operating margin
-638.5%
Net margin
0.0%
ROE
-255.9%
ROA
-74.2%
Health
Liquidity and balance-sheet strength
Debt / equity
0.65x
Current ratio
2.36x
Quick ratio
1.32x
Total debt
$3.15M
Total cash
$3.59M
Growth
How the business has been compounding
Revenue TTM
$3.31M
Revenue 5Y CAGR
13.8%
EPS TTM
-4.91
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-8.97M
Free CF TTM
$-8.76M
FCF margin
-264.4%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—